U.S., March 3 -- ClinicalTrials.gov registry received information related to the study (NCT07442292) titled 'PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor' on Feb. 24.
Brief Summary: The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Study Start Date: Feb., 2026
Study Type: OBSERVATIONAL
Condition:
Lung Cancer (NSCLC)
Lung Cancer (SCLC)
Melanoma (Skin Cancer)
Melanoma Metastatic
PD-L1
PET / CT
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Peking University Cancer Hospital & Institute
Info...